Lv52
1090 积分 2021-02-15 加入
Anti-CD20 monoclonal antibodies in multiple sclerosis: Rethinking the current treatment strategy
4小时前
已完结
Sinusoidal obstruction syndrome associated with disseminated toxoplasmosis involving the liver after allogeneic hematopoietic stem cell transplantation: A case report
6天前
已关闭
Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high
14天前
已完结
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
27天前
已完结
Tunlametinib: First Approval
1个月前
已完结
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial
1个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
1个月前
已完结
ATG-Thymoglobulin Versus ATG-Fresenius for Conditioning in Thalassemia Patients Who Underwent Allogenic Stem Cell Transplantation from Matched-Sibling Donor: A Tertiary Cancer Care Center Short-Term Experience
1个月前
已完结
A Developer’s Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10
3个月前
已完结
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
3个月前
已完结
皖公网安备34019202002308
